Articles

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

University Hospital of Salamanca/IBSAL, Salamanca, Spain
Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia
Winship Cancer Institute, Emory University, Atlanta, GA, USA
University Hospital Brno, Brno, Czech Republic
University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
Institute of Hematology Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
St James’s Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom
Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France
Levine Cancer Institute/Atrium Health, Charlotte, NC, USA
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada
Janssen Research and Development, LLC, Spring House, PA, USA
Janssen Global Medical Affairs, Horsham, PA, USA
Janssen Research & Development, LLC, Raritan, NJ, USA
Janssen Research and Development, LLC, Spring House, PA, USA
Janssen Research and Development, LLC, Spring House, PA, USA
National and Kapodistrian University of Athens, Athens, Greece
Vol. 105 No. 2 (2020): February, 2020 https://doi.org/10.3324/haematol.2019.217448